Article Text

SAT0349 A Tailored Approach to Reduce Dose of Anti-TNF Drugs is Equally Effective, but Substantially Less Costly than Standard Dosing in Patients with Ankylosing Spondylitis over One Year: A Matched Observational Study
  1. J. Zavada1,
  2. M. Uher2,
  3. K. Sisol1,
  4. S. Forejtova1,
  5. K. Jarosova1,
  6. H. Mann1,
  7. J. Vencovsky1,
  8. K. Pavelka1
  1. 1Institute Of Rheumatology, Prague
  2. 2Institute of Biostatistics and Analyses, Masaryk University, Brno, Czech Republic


Objectives To compare efficacy, safety and costs of standard versus individually tailored reduced doses of anti-TNF drugs in patients with ankylosing spondylitis (AS) after achieving low disease activity over one year

Methods One year outcome was compared between two prospectively followed cohorts of AS patients treated in a single academic centre with either reduced doses (n=53), or standard doses (n=83) of anti-TNF drugs. Both treatment groups were matched for patients' age, gender, baseline activity, baseline function, duration of anti-TNF therapy and number of previous anti-TNF drugs. The change in measures of disease activity, physical function, and quality of life, as well as number of relapses, adverse events and costs of anti-TNF drugs were compared between both groups. The study covered the time period between 2007 and 2013

Results In the reduced dosing group at baseline (after initial dose reduction) the median dose was 67% of standard dose, and 50% at 12 months; in 21% patients the dose was further decreased during one year of observation, while the same proportion of patients required a return to standard dosing regimen. All measures of activity and function, as well as their mean change, were comparable between both treatment groups at baseline and at 12 months of observation. The incidence of relapses, adverse events, severe adverse events, infections, infusion reactions and switches between anti-TNF drugs did not differ between both treatment groups. While the quality of life did not differ between both groups, the annual costs of anti-TNF therapy were substantially lower (by about one third) in the group with reduced dosing.

Table 1

Conclusions A tailored approach to reduce doses of anti-TNF drugs in patients with AS after reaching low disease activity was a cost-effective strategy over one year of treatment.

Acknowledgements This work was supported by the project (Ministry of Health, Czech Republic) for conceptual development of research organization 00023728.

Disclosure of Interest None declared

DOI 10.1136/annrheumdis-2014-eular.3351

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.